Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntingtons Disease Therapeutics Conference April 27, 2021 03:00 ET | Source: AFFiRiS AG AFFiRiS AG Vienna, AUSTRIA Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology Human mtHTT transgenic mice treated with mAB C6-17 showed signi...
Amber Southwell Division Of Neuroscience Burnett School Of Biomedical Sciences Annual Huntington Disease Therapeutics Chief Technology Officer
Source: globenewswire.com